Continuous Correction
Primary Purpose
Type 1 Diabetes
Status
Terminated
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Continuous Correction
Sponsored by
About this trial
This is an interventional treatment trial for Type 1 Diabetes focused on measuring Type 1 diabetes, Continuous Glucose Monitoring, Insulin pump, Sensor-augmented pump, Continuous correction of high blood glucose
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- T1D ≥ 3 years
- CSII ≥ 1 year
- HbA1c ≤ 8.0% (64 mmol/mol)
Exclusion Criteria:
- Pregnancy or nursing
- Hypoglycemia unawareness
- Gastroparesis
- Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during or within 30 days prior to the study
- Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation
Sites / Locations
- Hvidovre University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Continuous correction
Control
Arm Description
The insulin pump is set to automatically deliver the patient's usual insulin basal rate. The insulin pump bolus calculator is run every 10 minutes by the attending physician. Bolus calculations are based on glucose sensor values.
Regular sensor-augmented pump therapy.
Outcomes
Primary Outcome Measures
Percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00.
The primary outcome is difference in the percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00 on CC-days and Control-days.
Secondary Outcome Measures
Mean CGM glucose value.
Percentage of time when CGM values are < 3.9 mmol/l.
Percentage of time when CGM values are > 8.0 mmol/l.
CGM standard deviation.
Number of hypoglycemic episodes.
Amount of insulin delivered.
Positive Incremental Area Under the Curve
Full Information
NCT ID
NCT02162004
First Posted
June 2, 2014
Last Updated
August 30, 2016
Sponsor
Hvidovre University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02162004
Brief Title
Continuous Correction
Official Title
Sensor-Augmented Continuous Correction in Insulin Pump-Treated Type 1 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Terminated
Why Stopped
Technical problems
Study Start Date
June 2014 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hvidovre University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The potential of currently available diabetes technologies could be further exploited. The investigators propose that sensor-augmented insulin pump therapy may be improved by continuous correction, i.e. continuous evaluation of the need for correction boluses. In practice, this is carried out by running the bolus calculator every 10 minutes. The glucose sensor will provide the bolus calculator with glucose input. Many times, the bolus calculator will come to the result that no insulin is needed. However, when the blood glucose is above the pre-set target value and a correction bolus is needed, an appropriate bolus is automatically delivered by the insulin pump.
The investigators hypothesize that sensor-augmented continuous correction insulin pump therapy can reduce hyperglycemia without increasing the risk of hypoglycemia in patients with type 1 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
Type 1 diabetes, Continuous Glucose Monitoring, Insulin pump, Sensor-augmented pump, Continuous correction of high blood glucose
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Continuous correction
Arm Type
Experimental
Arm Description
The insulin pump is set to automatically deliver the patient's usual insulin basal rate. The insulin pump bolus calculator is run every 10 minutes by the attending physician. Bolus calculations are based on glucose sensor values.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Regular sensor-augmented pump therapy.
Intervention Type
Procedure
Intervention Name(s)
Continuous Correction
Primary Outcome Measure Information:
Title
Percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00.
Description
The primary outcome is difference in the percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00 on CC-days and Control-days.
Time Frame
Every 5 min for 9 hours on each study day.
Secondary Outcome Measure Information:
Title
Mean CGM glucose value.
Time Frame
Every 5 min for 9 hours on each study day.
Title
Percentage of time when CGM values are < 3.9 mmol/l.
Time Frame
Every 5 min for 9 hours on each study day.
Title
Percentage of time when CGM values are > 8.0 mmol/l.
Time Frame
Every 5 min for 9 hours on each study day.
Title
CGM standard deviation.
Time Frame
Every 5 min for 9 hours on each study day.
Title
Number of hypoglycemic episodes.
Time Frame
Every 5 min for 9 hours on each study day.
Title
Amount of insulin delivered.
Time Frame
Every 30 min for 9 hours on each study day.
Title
Positive Incremental Area Under the Curve
Time Frame
Every 5 min for 9 hours on each study day.
Other Pre-specified Outcome Measures:
Title
Mean absolute relative difference.
Description
CGM accuracy will be evaluated with Hemocue glucose values as reference (mean absolute relative difference).
Time Frame
Every 5 min for 9 hours on each study day.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
T1D ≥ 3 years
CSII ≥ 1 year
HbA1c ≤ 8.0% (64 mmol/mol)
Exclusion Criteria:
Pregnancy or nursing
Hypoglycemia unawareness
Gastroparesis
Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during or within 30 days prior to the study
Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Signe Schmidt, MD, PhD
Organizational Affiliation
Hvidovre University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hvidovre University Hospital
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Continuous Correction
We'll reach out to this number within 24 hrs